Compare OLP & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | ZVRA |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.4M | 472.9M |
| IPO Year | 1995 | 2015 |
| Metric | OLP | ZVRA |
|---|---|---|
| Price | $23.52 | $8.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 55.1K | ★ 540.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | N/A | ★ 34.27 |
| EPS | 1.05 | ★ 1.16 |
| Revenue | ★ $82,740,000.00 | $23,612,000.00 |
| Revenue This Year | $8.03 | $333.64 |
| Revenue Next Year | $7.26 | $44.19 |
| P/E Ratio | $22.78 | ★ $7.73 |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $6.19 |
| 52 Week High | $28.36 | $13.16 |
| Indicator | OLP | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 65.24 | 47.42 |
| Support Level | $23.29 | $8.61 |
| Resistance Level | $23.93 | $8.99 |
| Average True Range (ATR) | 0.49 | 0.34 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 78.45 | 33.54 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.